Table III.

ART treatments, criteria for choice of centre and sources of information used by 128 French CBRC patients.

	All patients (n = 128)		Oocyte donation				Sperm donation		Other casesa (n = 24)		Key differences between groupsb
			Greece (n = 22)		Spain (n = 65)		Belgium (n = 17)
	n	%	n	%	n	%	%	n	n	%
Previous use of ART in France											Greece + Spain versus Belgium: P-χ2 < 0.01
Yes	74	58	15	68	49	75	1	6	9	37
No	54	42	7	32	16	25	16	94	15	63
Membership of a patients' organization											Greece versus Spain versus Belgium: P-χ2 < 0.01
Yes	53	42	20	91	26	40	3	18	4	17
No	74	58	2	9	39	60	14	82	19	83
A patients' organization recommended the centre											Greece versus Spain versus Belgium: P-Fisher < 0.01
Yes	27	21	17	77	8	12	0	0	2	8
No	101	79	5	23	57	88	17	100	22	92
A physician recommended the centre											Greece versus Spain versus Belgium: P-χ2 < 0.01
Yes	73	57	3	14	54	83	1	6	15	63
No	55	43	19	86	11	17	16	94	9	37
Geographical proximity											Greece versus Spain versus Belgium: P-Fisher < 0.01
Was a criterion	27	21	0	0	8	12	12	71	7	30
Was not a criterion	100	79	22	100	57	88	5	29	16	70
Cost											Greece versus Spain versus Belgium: P-Fisher < 0.01
Was a criterion	24	19	20	91	1	2	1	6	2	9
Was not a criterion	103	81	2	9	64	98	16	94	21	91
Reimbursement in France requested
Yes	52	41	7	32	32	49	8	47	5	22
No	75	59	15	68	33	51	9	53	18	78
Difficulties in using ART abroad											Greece + Spain versus Belgium: P-χ2 < 0.01
Yes	52	41	9	41	19	30	14	82	10	42
No	74	59	13	59	44	70	3	18	14	58

^a‘Other cases’ are detailed in Table I. They included French CBRC patients treated in Spain using sperm donation (n = 5), both sperm and oocyte donation (n = 5), embryo donation (n = 1), IVF (n = 6) and oocyte cryopreservation (n = 5), as well as patients treated in Belgium using surrogacy (n = 2).

^bP-χ² if the test is the χ² test, P-Fisher if the test is the Fisher test.